Share on StockTwits

Equities researchers at Goldman Sachs started coverage on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research report issued on Wednesday. The firm set a “neutral” rating on the stock.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 248.135 on Wednesday. Intercept Pharmaceuticals has a 1-year low of $42.41 and a 1-year high of $497.00. The stock has a 50-day moving average of $258.3 and a 200-day moving average of $280.3. The company’s market cap is $5.232 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings data on Wednesday, May 7th. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-14.92 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $425.00 price target on the stock. Separately, analysts at Summer Street reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Friday, June 27th. Finally, analysts at Leerink Swann initiated coverage on shares of Intercept Pharmaceuticals in a research note on Thursday, June 26th. They set a “market perform” rating and a $270.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $481.63.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.